ATE318326T1 - Verwendung von in neuriten lokalisierten mrnas zur medizinischen diagnose und therapie - Google Patents

Verwendung von in neuriten lokalisierten mrnas zur medizinischen diagnose und therapie

Info

Publication number
ATE318326T1
ATE318326T1 AT95939944T AT95939944T ATE318326T1 AT E318326 T1 ATE318326 T1 AT E318326T1 AT 95939944 T AT95939944 T AT 95939944T AT 95939944 T AT95939944 T AT 95939944T AT E318326 T1 ATE318326 T1 AT E318326T1
Authority
AT
Austria
Prior art keywords
neurites
mrnas
localized
therapy
mrna expression
Prior art date
Application number
AT95939944T
Other languages
English (en)
Inventor
James Eberwine
Marc Dichter
Kevin Miyashiro
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23306347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE318326(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE318326T1 publication Critical patent/ATE318326T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95939944T 1994-11-03 1995-11-03 Verwendung von in neuriten lokalisierten mrnas zur medizinischen diagnose und therapie ATE318326T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/334,254 US5723290A (en) 1994-11-03 1994-11-03 Methods for profiling mRNA expression in neurites

Publications (1)

Publication Number Publication Date
ATE318326T1 true ATE318326T1 (de) 2006-03-15

Family

ID=23306347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939944T ATE318326T1 (de) 1994-11-03 1995-11-03 Verwendung von in neuriten lokalisierten mrnas zur medizinischen diagnose und therapie

Country Status (8)

Country Link
US (1) US5723290A (de)
EP (1) EP0787206B1 (de)
JP (2) JP4382159B2 (de)
AT (1) ATE318326T1 (de)
CA (1) CA2204433C (de)
DE (1) DE69534802T2 (de)
ES (1) ES2256852T3 (de)
WO (1) WO1996014435A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379897B1 (en) * 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6469779B2 (en) 1997-02-07 2002-10-22 Arcturus Engineering, Inc. Laser capture microdissection method and apparatus
US6495195B2 (en) * 1997-02-14 2002-12-17 Arcturus Engineering, Inc. Broadband absorbing film for laser capture microdissection
US6100051A (en) 1997-06-27 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Method utilizing convex geometry for laser capture microdissection
US7075640B2 (en) * 1997-10-01 2006-07-11 Arcturus Bioscience, Inc. Consumable for laser capture microdissection
US20050084875A1 (en) * 1997-10-24 2005-04-21 University Of Rochester Molecular markers for the diagnosis of Alzheimer's disease
US6114152A (en) * 1997-12-12 2000-09-05 The Regents Of The University Of California Methods for making nucleic acids
EP1038009A1 (de) 1997-12-12 2000-09-27 The Regents of the University of California Methode zur bestimmung des zelltyps
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
EP1101094B1 (de) * 1998-07-30 2004-09-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Präzisions-laseranheftungs-mikrodissektion mittels kurzer impulsdauer
EP1210577A2 (de) 1999-04-29 2002-06-05 Arcturus Engineering, Inc. Verwendung von laminierungstechnik bei der vorbereitung von proben zur laseranheftungs-mikrodissektion
US20020187924A1 (en) * 1999-12-17 2002-12-12 James Eberwine Compositions and methods for modulating and monitoring neurotransmitter receptor populations
EP1269144A1 (de) 2000-02-16 2003-01-02 Arcturus Engineering, Inc. Transferfilm für laseranheftungs-mikrodissektion
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
US6391592B1 (en) * 2000-12-14 2002-05-21 Affymetrix, Inc. Blocker-aided target amplification of nucleic acids
TWI335938B (en) * 2001-08-15 2011-01-11 Rna replication and amplification
US6852494B2 (en) * 2003-01-10 2005-02-08 Linden Technologies, Inc. Nucleic acid amplification
US20040220125A1 (en) * 2003-05-02 2004-11-04 Coles John G. Biosynthetic platform for cardioprotective gene expression using immature heart tissue
US20050054599A1 (en) * 2003-05-02 2005-03-10 Coles John G. Biosynthetic platform for cardioprotective stress response in human fetal heart tissue
GB2422196B (en) * 2003-05-20 2008-05-07 Investigen Inc System for detecting polynucleotides
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
WO2005003370A2 (en) * 2003-06-06 2005-01-13 Gene Logic, Inc. Methods for enhancing gene expression analysis
US20050221310A1 (en) * 2003-06-06 2005-10-06 Gene Ogic, Inc. Methods for enhancing gene expression analysis
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
EP2010677A4 (de) * 2006-02-24 2010-04-14 Investigen Inc Verfahren und zusammensetzungen zum nachweis von polynukleotiden
US20090188091A1 (en) * 2006-04-27 2009-07-30 Libeltex Bvba Method for producing polymeric fiber insulation batts for residential and commercial construction applications
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
WO2008103702A2 (en) * 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
WO2011130728A1 (en) 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416197A (en) * 1993-10-15 1995-05-16 Trustees Of The University Of Pennsylvania Antibodies which bind human collapsin
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use

Also Published As

Publication number Publication date
WO1996014435A1 (en) 1996-05-17
JP4382159B2 (ja) 2009-12-09
EP0787206A4 (de) 1998-12-02
US5723290A (en) 1998-03-03
DE69534802T2 (de) 2006-08-17
JP2006068021A (ja) 2006-03-16
CA2204433A1 (en) 1996-05-17
EP0787206B1 (de) 2006-02-22
DE69534802D1 (de) 2006-04-27
CA2204433C (en) 2009-09-15
ES2256852T3 (es) 2006-07-16
JPH10508490A (ja) 1998-08-25
EP0787206A1 (de) 1997-08-06

Similar Documents

Publication Publication Date Title
DE69534802D1 (de) VERWENDUNG VON IN NEURITEN LOKALISIERTEN mRNAs ZUR MEDIZINISCHEN DIAGNOSE UND THERAPIE
Knittel et al. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-) fibroblast subpopulations in hepatic tissue repair
ATE243538T1 (de) Neues verfahren zur herstellung von mitteln zur oberflächenbehandlung
Burckhardt et al. Pain-coping strategies of women with fibromyalgia: relationship to pain, fatigue, and quality of life
ATE547708T1 (de) Verfahren zur handhabung der kinasehemmertherapie
ATE189957T1 (de) Verwendung von nadph-oxidase-inhibitoren zur herstellung eines arzneimittels zur vorbeugung der arteriosklerose
ATE364089T1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
DE69637179D1 (de) Angiostatinfragmente und verfahren für deren verwendung
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DE60016242D1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
ATE347697T1 (de) Methode zur bestimmung von proteinfragmenten in körperflüssigkeiten
DE69929787D1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
ATE283703T1 (de) Neurodegenerative-erkrankung verwandtes gen
ATE286253T1 (de) Methoden zur diagnose oder prognose der alzheimerschen krankheit
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
ATE335759T1 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
DE69739653D1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
Harbourne et al. The effect of operation and subcutaneous heparin on plasma levels of antithrombin-III
ATE312914T1 (de) Rdgb-proteine
FI951778A0 (fi) Menetelmä allergian toteamiseksi
ATE401576T1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties